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Summary
There are no validated markers for predicting benefit from angiogenesis inhibitors or classifying tumors with distinct angiogenic phenotypes. In NSCLC patients treated with bevacizumab and erlotinib, Franzini and colleagues find that angiogenesis-and hypoxiaassociated gene expression signatures predict tumor response and/or clinical outcome, and may define distinct angiogenic patterns.
Research. Given this progress, it is perhaps surprising that after about two decades of testing angiogenesis inhibitors such as the anti-VEGF monoclonal antibody bevacizumab, we still do not have clinically useful markers for classifying tumors based on their angiogenic phenotype, or for predicting which patients are more likely to benefit from these drugs. This is surely an important unmet need, given that only a minority of patients derive significant benefit from bevacizumab, serious toxicities may occur, and resistance inevitably occurs. population, but two randomized phase III studies suggest that bevacizumab plus erlotinib may be superior to erlotinib alone among EGFR mutation positive patients (4, 5) . Outside of EGFR mutation, there are currently no validated markers for identifying which patients are more likely to benefit from bevacizumab when added to either chemotherapy or erlotinib. were found to have prognostic value for OS, as the median OS for patients with elevated hypoxia signature expression was 9.9 months versus 17.8 months in patients with decreased levels. While hypoxia-inducible factor 1-alpha (HIF-1α) was not identified as predictive for TTP, several of its downstream targets were components of the hypoxia signature. These results agree with previously reported studies demonstrating that hypoxia correlates with a more aggressive phenotype, perhaps by enhancing malignant potential through increased genomic instability and by acting as selective pressure for variants with diminished apoptotic potential (7).
Assuming the associations described between the angiogenic and hypoxia response signatures are robust, important issues would need to be addressed before they could be used in selecting therapy. In the absence of a control arm, it is not possible to determine whether the signatures are predictive of benefit for bevacizumab plus erlotinib compared with another therapy, or merely prognostic. Caution should be used in assuming that markers associated with improved clinical outcome in a single arm study will be predictive of greater relative benefit compared with another drug in a randomized study. For example, we previously observed that high circulating IL-6 is a negative prognostic marker in metastatic renal cell cancer, but predicts greater relative benefit for patients receiving pazopanib compared with placebo control (8) . Such observations would not be evident in a single arm study.
Clinically useful predictive biomarkers typically help inform the choice between different therapies. It remains to be seen whether the angiogenic or hypoxia signatures could be used to predict, for example, which patients benefit from bevacizumab in combination with chemotherapy compared with chemotherapy alone. Interestingly, the authors report an association between the hypoxia signature and PFS in the sorafenib, but not erlotinib, arm of the BATTLE study, suggesting the signature may have utility for other drugs targeting the VEGF pathway (9, 10).
Given the current NSCLC landscape, it would also be important to assess whether the signatures are predictive of benefit within the standard molecularly defined subgroups.
As noted above, bevacizumab appears to add greater benefit in the EGFR mutation positive subgroup (4, 5) . It would therefore be important to assess the signatures in the EGFR-mutant and wild-type groups separately. The mechanism underlying the apparently increased sensitivity of EGFR mutant tumors to VEGF blockade is not well understood, but it is noteworthy that constitutive EGFR pathway activation results in upregulation of VEGF and the HIF-1α pathway (11) 
